OrbiMed’s Zymeworks ZYME Stock Holding History

OrbiMed’s Portfolio ZYME Stock Details ZYME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-317,002	Closed	-$15M	–	181
2020 Q4	$15M	Sell	317,002 -24,100	-7%	-$1.12M	0.13%	111
2020 Q3	$15.9M	Sell	341,102 -241,200	-41%	-$8.28M	0.2%	96
2020 Q2	$21M	Hold	582,302	–	–	0.3%	75
2020 Q1	$20.7M	Buy	+582,302	New	+$23.8M	0.35%	65

Other funds holding ZYME

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

OrbiMed's ZYME Position: Q1 2021 in Review

OrbiMed sold out of Zymeworks (ZYME) in Q1 2021, closing a stake of 317,002 shares — an estimated $15M sold.

OrbiMed first reported a position in ZYME in Q1 2020 and held it in 4 quarters. The position peaked at $21M in Q2 2020. 125 funds tracked by Wall St. Rank hold ZYME as of Q1 2021.

OrbiMed reported no remaining Zymeworks position as of Q1 2021 after selling out during the quarter.
OrbiMed sold 317,002 Zymeworks shares in Q1 2021, an estimated $15M.
OrbiMed first reported a position in Zymeworks in Q1 2020 and held it in 4 quarters.
OrbiMed's Zymeworks position peaked at $21M in Q2 2020.
125 funds tracked by Wall St. Rank held Zymeworks as of Q1 2021.

Based on OrbiMed's 13F filing for Q1 2021, filed 17 May 2021.